RxDoctor Payments Data

Himanshu Aggarwal, MD

Ophthalmology · Taylor, MINPI 1356505010

Payments from drug & device makers

$2,878in general payments, 2019–2025

Across 70 payments — averaging $41.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sight Sciences, Inc.$1K
  • Alcon$561
  • Tarsus Pharmaceuticals, Inc.$129
  • Regeneron Healthcare Solutions, Inc.$116
  • Genentech USA, Inc.$113
  • Glaukos Corporation$91
  • plus $410 from 13 others

What the payments were for

  • Food & beverage$2,85999%
  • Gifts$191%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,878 in reported general payments places this provider in the 70th percentile of 674 ophthalmology providers in Michigan.

See all ophthalmology providers in Michigan

Medicare billing

Part B allowed, 2024
$412,661
Medicare patients
706
Services billed
3,521

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine70$50,316
Prednisolone Acetate627$27,132
RocklatanNetarsudil Mesylat/Latanoprost56$26,991
LumiganBimatoprost48$18,342
RhopressaNetarsudil Mesylate29$17,498
Latanoprost916$15,279
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat539$10,606
Cyclosporine28$8,777
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol37$8,091
CombiganBrimonidine Tartrate/Timolol22$8,037
Fluorometholone77$6,685
Cromolyn Sodium373$5,734
Timolol Maleate183$5,335
Ofloxacin334$4,270
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha227$3,259

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan$63$76,695140 claims
Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa$13$44,48985 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 674 ophthalmology providers in Michigan.

Other ophthalmology in Taylor

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →